Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 0 1 427 4 6 9 2,108
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 1 295 0 1 6 1,323
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 0 842
Generic drug pricing in Canada: components of the value-chain 0 0 2 106 2 4 6 332
Microcredit in Pre-Famine Ireland 0 1 2 337 0 2 7 1,773
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 2 4 5 170
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 1 2 4 284
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 1 3 6 249
Subsidizing the Competition 0 0 0 134 1 2 2 684
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 0 324 1 2 6 1,593
Total Working Papers 0 1 6 1,893 12 26 51 9,358


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 1 547 2 3 4 4,115
A contractual approach to the gray market 0 0 0 123 1 2 8 411
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 0 0 0 2 5 8 11
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 2 3 4 4
Co-authorship and the output of academic economists 0 0 0 72 2 6 8 257
Competition policy in open economies 0 0 0 32 1 2 4 170
Der Green Impact Fund for Technology 0 0 0 3 0 0 5 16
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 0 0 0 18
Governance of electricity transmission systems 0 0 0 81 2 4 5 217
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 0 0 1 191 0 2 6 490
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 4 5 6 20
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 1 2 2 106
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 0 0 2 20
Microcredit in Prefamine Ireland 1 1 2 63 1 2 6 271
Microcredit: What can we learn from the past? 0 0 2 328 0 1 5 972
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 0 1 98 2 4 9 447
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 1 3 33 1 3 7 123
Patient income and health innovation 0 0 0 11 2 2 5 43
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 0 0 1 1
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 2 2 3 334
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 2 3 37
Strategic Implications of Learning by Doing 0 0 0 87 2 5 5 566
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 0 15 2 2 7 44
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 1 2 5 732
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 1 1 2 85
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 0 2 1 3 5 17
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 1 2 2 3
The importance of being first: evidence from Canadian generic pharmaceuticals 1 2 7 310 3 8 14 726
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 0 60 3 6 9 169
The life-cycle of a microfinance institution: the Irish loan funds 0 0 1 157 2 2 6 461
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 1 2 34
Total Journal Articles 2 4 18 2,595 41 82 158 10,920


Statistics updated 2026-01-09